Alexandria Pharmaceuticals results, Q3 2024
Net profit, assets, equity and cash flow for Q3 2024, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit217 millionEGP · +71.4% vs the same period a year earlier
Total assets1.24 billionEGP · +34.5% vs the same period a year earlier
Shareholders' equity795 millionEGP · +20.4% vs the same period a year earlier
Operating cash flow190 millionEGP · +107.6% vs the same period a year earlier
In short
- Alexandria Pharmaceuticals's net profit for Q3 2024 was about 217 million EGP, up +71.4% from 126 million EGP in Q3 2023.
- Total assets at the end of Q3 2024 were about 1.24 billion EGP, and shareholders' equity about 795 million EGP.
- Operating cash flow for Q3 2024 was positive at 190 million EGP.
Key lines against the same period a year earlier
This periodQ3 2023Change
Net profit217 million126 million+71.4%
Gross profit613 million295 million+107.4%
Total assets1.24 billion923 million+34.5%
Total liabilities446 million263 million+69.7%
Shareholders' equity795 million660 million+20.4%
Total liabilities and equity1.24 billion923 million+34.5%
Operating cash flow190 million91.34 million+107.6%
Investing cash flow-48.33 million-77.84 million+37.9%
Financing cash flow-82 million-76.94 million−6.6%
Net change in cash59.3 million-63.44 million+193.5%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Alexandria Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy